



10745 Westside Way, Suite 200
Alpharetta, GA 30009
Tel: +1 (844) 884 5367
Email: info@vtivision.com
www.vtivation.com
www.vtivationinvestors.com (for investors)

ASX Announcement

RELEASE OF SHARES and CDIs FROM ESCROW

Atlanta, Georgia, USA 13 September 2017: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses advises that in connection with the Company's quotation on the Australian Securities Exchange on 28 March 2017, particular security holders of the Company were required to enter into voluntary and ASX-imposed escrow arrangements. The voluntary and ASX-imposed escrow agreements provided that the relevant security holders would be restricted from dealing in their securities for periods of up to 24 months from the date of official quotation of the Company's CHESS Depository Interests (**CDIs**) on the ASX.

Pursuant to ASX Listing Rule 3.10A, the Company advises that a number of shares of the Class A common stock of the Company (**Shares**) and CDIs are due for release from ASX imposed escrow on 27 September 2017 as follows:

Shares

A total of 36,975,027 Shares (equivalent to the same number of CDIs) are due to be released from voluntary escrow on 27 September 2017. All of these Shares will be freely tradeable.

CDIs

A total of 16,359,293 CDIs (equivalent to the same number of Shares) are due to be released from voluntary escrow on 27 September 2017. Out of the total 16,359,293 CDIs being released from voluntary escrow, 21,125 CDIs will remain subject to voluntary escrow and 16,338,168 CDIs will be freely tradeable.

Leanne Ralph
Company Secretary

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).

NaturalVue lenses were cleared by the FDA in late 2014 and VTI recently commenced its US market expansion for NaturalVue MF contact lenses, following a successful pilot US market launch in 2015 and 2016. . VTI also sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR21 r1